Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Therapies inhibiting receptor tyrosine kinases (RTKs) are effective against some human cancers when they lead to simultaneous downregulation of PI3K/AKT and MEK/ERK signaling. However, mutant KRAS has the capacity to directly activate ERK and PI3K signaling, and this is thought to underlie the resistance of KRAS mutant cancers to RTK inhibitors. Here, we have elucidated the molecular regulation of both the PI3K/AKT and MEK/ERK signaling pathways in KRAS mutant colorectal cancer cells and identified combination therapies that lead to robust cancer cell apoptosis. KRAS knockdown using shRNA suppressed ERK signaling in all of the human KRAS mutant colorectal cancer cell lines examined. However, no decrease, and actually a modest increase, in AKT phosphorylation was often seen. By performing PI3K immunoprecipitations, we determined that RTKs, often IGF-IR, regulated PI3K signaling in the KRAS mutant cell lines. This conclusion was also supported by the observation that specific RTK inhibition led to marked suppression of PI3K signaling and biochemical assessment of patient specimens. Interestingly, combination of RTK and MEK inhibitors led to concomitant inhibition of PI3K and MEK signaling, marked growth suppression, and robust apoptosis of human KRAS mutant colorectal cancer cell lines in vitro and upon xenografting in mice. These findings provide a framework for utilizing RTK inhibitors in the treatment of KRAS mutant colorectal cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The IGF1R/ERBB2/3 signaling pathway may respond to the suppressed ERK and AKT signaling after KRAS (G12C) inhibitor treatment and favor the change to epithelial cell types (Fig. 5).”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [132]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our screens identified previously described MEKi sensitizers, including those that function through the PI3K/AKT/mTOR pathway (AKT1, AKT2, RICTOR, MTOR, and IGF1R), through suppression of ERK pathway feedback reactivation (or incomplete pathway inhibition) (BRAF, RAF1, MAPK1, MAPK3, KRAS, and FGFR1), and through the YAP1 pathway”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Ebi et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which is consistent with prior studies suggesting that PI3K is not universally tied to RAS activity (15,29).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“the combined inhibition of MEK and the PI3K/AKT/mTOR pathway has been widely described”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Ebi et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“High basal ERBB2/3 associated with epithelial gene signatures was observed in KRAS (G12C) cell lines and human lung cancers.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [132]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationAnaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Research works printed but not linked: 2
- Yakes, 2002, Cancer Res., 62, 4132
- Guix, 2008, J Clin Invest., 118, 2609
Cited by
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
“Constitutive activation of PI3K, via overexpression of PIK3CA mutants, conferred resistance to the antibody in laboratory studies (Chakrabarty et al., 2010; Eichhorn et al., 2008; Serra et al., 2008).”
BackgroundSelf-citationCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Self-citationHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
“Corroborating our results, several of the synergistic pairs were previously identified with alternative screening methods, such as the combination of IGF1R and MEK inhibitors (44, 45).”
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Self-citationVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
“Interestingly, the effects of KRAS or SHP2 inhibition on PI3K/AKT signaling, as measured by phospho-AKT, were highly variable across cell lines, with a reduction noted in some cell lines (SW1463, MIA PaCa-2, NCIH23, NCIH358), and unaffected or increased levels noted in other cell lines, which is consistent with prior…”
ResultSelf-citationRoles for KRAS in Pancreatic Tumor Development and Progression
di Magliano, M. P., & Logsdon, C. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.071 · Cited by 400
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Taniguchi, H., Yamada, T., Wang, R., Tanimura, K., Adachi, Y., Nishiyama, A., Tanimoto, A., Takeuchi, S., Araujo, L. H., Boroni, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08074-0 · Cited by 356
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368
Self-citationEser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360
Allen, J. E., Krigsfeld, G., Mayes, P. A., Patel, L., Dicker, D. T., Patel, A. S., Dolloff, N. G., Messaris, E., Scata, K. A., Wang, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004828 · Cited by 342
Colorectal cancer carcinogenesis: a review of mechanisms
Tariq, K., Tariq, K., Ghias, K., & Ghias, K. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2015.0103 · Cited by 304
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R.-P., Rabinovich, B. A., Hann, B., Dankort, D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304
“Upregulation of RTKs in colon cancer in response to MEK inhibition was also seen by others (Ebi et al., 2011).”
BackgroundJanku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer
Aubert, L., Nandagopal, N., Steinhart, Z., Lavoie, G., Nourreddine, S., Berman, J., Saba-El-Leil, M. K., Papadopoli, D., Lin, S., Hart, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17549-y · Cited by 287
Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 263
Self-citationTAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers
Singh, A., Sweeney, M. F., Yu, M., Burger, A., Greninger, P., Benes, C., Haber, D. A., & Settleman, J. (2012) · Cell · doi:10.1016/j.cell.2011.12.033 · Cited by 260
Self-citationKRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
“Thus, we show that the PI3K pathway is not under the sole control of mutant KRAS in KRAS G12C NSCLC models, and perhaps tumors, as shown previously in colorectal models (22).”
BackgroundSelf-citationAdachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
“Dominant regulation of PI3K signaling through IGFR was also previously reported in KRAS-mutant colorectal and lung cancers (33, 34).”
BackgroundSelf-citationTargeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1010 · Cited by 211
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
Ebi, H., Costa, C., Faber, A. C., Nishtala, M., Kotani, H., Juric, D., Della Pelle, P., Song, Y., Yano, S., Mino-Kenudson, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314124110 · Cited by 210
Self-citationDevelopment of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203
KRAS drives immune evasion in a genetic model of pancreatic cancer
Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 191
Simpson, A., Petnga, W., Macaulay, V. M., Weyer-Czernilofsky, U., & Bogenrieder, T. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0514-5 · Cited by 183
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2013) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 167
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 166
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Self-citationMolina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157
“A study of KRAS mutant colon cancer cell lines recently reported a clear tendency towards sensitivity to IGF1R inhibition (45).”
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Xu, J., Xiao, Y., Liu, B., Pan, S., Liu, Q., Shan, Y., Li, S., Qi, Y., Huang, Y., & Li, J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01562-6 · Cited by 159
Clinical relevance of colorectal cancer molecular subtypes
Rodríguez-Salas, N., Dominguez, G., Barderas, R., Mendiola, M., García‐Albéniz, X., Maurel, J., & Batlle, J. F. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.007 · Cited by 170
Roberts, P. J., Usary, J. E., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., Duncan, J. S., Johnson, S. M., Combest, A. J., Jin, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0563 · Cited by 138
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
Yohe, M. E., Gryder, B. E., Shern, J. F., Song, Y. K., Chou, H.-C., Sindiri, S., Mendoza, A., Patidar, R., Zhang, X., Guha, R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4470 · Cited by 145
Self-citationThe Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 138
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
“Interestingly, RTK driven PI3K activity has been shown to be important for growth and survival even in the context of KRAS mutant colorectal cells, though no relationship to EMT was described (32).”
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Self-citationWang, X., Liang, Z. C., Xu, X., Li, J., Zhu, Y., Meng, S., Li, S., Wang, S., Xie, B., Ji, A., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.373 · Cited by 126
Liu, B., Pan, S., Xiao, Y., Liu, Q., Xu, J., & Li, J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0994-x · Cited by 122
RetractedZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism
Yang, Y., Ahn, Y.-H., Chen, Y., Tan, X., Guo, L., Gibbons, D. L., Ungewiss, C., Peng, D. H., Liu, X., Lin, S. H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72171 · Cited by 115
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 110
Kirouac, D. C., Du, J. Y., Lahdenranta, J., Overland, R., Yarar, D., Paragas, V., Pace, E., McDonagh, C. F., Nielsen, U. B., & Onsum, M. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004008 · Cited by 105
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V., Xu, L., Kohli, N., Rennard, R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 103
SOS GEFs in health and disease
Baltanás, F. C., Zarich, N., Rojas-Cabañeros, J. M., & Santos, E. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188445 · Cited by 100
Hiraki, M., Nishimura, J., Takahashi, H., Wu, X., Takahashi, Y., Miyo, M., Nishida, N., Uemura, M., Hata, T., Takemasa, I., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.5 · Cited by 95
Vitiello, P. P., Cardone, C., Martini, G., Ciardiello, D., Belli, V., Matrone, N., Barra, G., Napolitano, S., Della Corte, C., Turano, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1035-0 · Cited by 96
Can EGFR be a therapeutic target in breast cancer?
Li, X., Zhao, L., Chen, C., Nie, J., & Jiao, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188789 · Cited by 110
Song, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95
“shRNA transduction methodology has been described previously (28).”
MethodSelf-citationMicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2
Fan, C., Lin, Y., Mao, Y., Huang, Z., Liu, A. Y., Ma, H., Yu, D., Maitikabili, A., Xiao, H., Zhang, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7989 · Cited by 96
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“Although some KRAS-driven cancers such as pancreatic cancers depend on the PI3K pathway, other KRAS-mutant tumors such as some lung or colorectal cancers do not (Ebi et al. 2011; Eser et al. 2013).”
BackgroundInfluentialMetastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells
Al-Aidaroos, A. Q., Yuen, H. F., Guo, K., Zhang, S., Chung, T., Chng, W. J., & Zeng, Q. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66824 · Cited by 91
Targeted therapies in colorectal cancer—an integrative view by PPPM
Hagan, S., Orr, M. C. M., & Doyle, B. J. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-3 · Cited by 106
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Pek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Pettazzoni, P., Viale, A., Shah, P., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 81
Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80
“(Corcoran et al., 2013; Ebi et al., 2011; Engelman et al., 2008; Lamba et al., 2014; Lin et al., 2015; Manchado et al., 2016; Sun et al., 2014).”
BackgroundLiu, B., Pan, S., Xiao, Y., Liu, Q., Xu, J., & Li, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1367-9 · Cited by 80
PI3K: A Crucial Piece in the RAS Signaling Puzzle
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 84
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Molina-Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 71
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
Self-citationPI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context
Schmit, F., Utermark, T., Zhang, S., Wang, Q., Von, T., Roberts, T. M., & Zhao, J. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323004111 · Cited by 72
Huang, M.-H., Lee, J., Chang, Y., Tsai, H.-H., Lin, Y., Lin, A. M.-Y., & Yang, J. C. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.002 · Cited by 78
Zins, K., Gunawardhana, S., Lucas, T., Abraham, D., & Aharinejad, S. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-295 · Cited by 68
Vakana, E., Pratt, S., Blosser, W., Dowless, M., Simpson, N., Yuan, X.-J., Jaken, S., Manro, J., Stephens, J., Zhang, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14002 · Cited by 70
Sato, H., Yamamoto, H., Sakaguchi, M., Shien, K., Tomida, S., Shien, T., Ikeda, H., Hatono, M., Torigoe, H., Namba, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13763 · Cited by 69
Choi, C., & Helfman, D. M. (2013) · Oncogene · doi:10.1038/onc.2013.341 · Cited by 70
Zhong, M., Chen, Y., Zhang, G., Xu, L., Ge, W., & Wu, B. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0866-2 · Cited by 71
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., & Stites, E. C. (2019) · Science Signaling · doi:10.1126/scisignal.aaw8288 · Cited by 65
Apoptosis In Targeted Therapy Responses
Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 72
Self-citationThe effects of mutant Ras proteins on the cell signalome
Takács, T., Kudlik, G., Kurilla, A., Szeder, B., Buday, L., & Vas, V. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09912-8 · Cited by 62
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Joshi, M., Rice, S. J., Liu, X., Miller, B., & Belani, C. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118210 · Cited by 64
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Sirvent, A., Bénistant, C., & Roche, S. (2012) · Europe PMC (PubMed Central) · Cited by 78
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 62
Chu, P., Lin, P., Wu, H.-Y., Lin, K., Wu, C. S.-Y., Bekaii‐Saab, T., Lin, Y., Lee, C., Lee, J.-C., & Chen, C. (2018) · Oncogene · doi:10.1038/s41388-018-0222-3 · Cited by 59
Fujita-Sato, S., Galeas, J., Truitt, M., Pitt, C., Urisman, A., Bandyopadhyay, S., Ruggero, D., & McCormick, F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1623 · Cited by 55
Sheffels, E., Sealover, N. E., Wang, C., Kim, D. H., Vazirani, I. A., Lee, E., M. Terrell, E., Morrison, D. K., Luo, J., & Kortum, R. L. (2018) · Science Signaling · doi:10.1126/scisignal.aar8371 · Cited by 56
Nakatani, K., Yamaoka, T., Ohba, M., Fujita, K., Arata, S., Kusumoto, S., Taki-Takemoto, I., Kamei, D., Iwai, S., Tsurutani, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0591 · Cited by 59
Zhou, Y., Tang, J., Du, Y., Ding, J., & Liu, J.-Y. (2016) · Tumor Biology · doi:10.1007/s13277-015-4719-x · Cited by 57
Solberg, N. T., Waaler, J., Lund, K., Mygland, L., Olsen, P. A., & Krauss, S. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0362 · Cited by 49
Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
Mologni, L., Brussolo, S., Ceccon, M., & Gambacorti-Passerini, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051449 · Cited by 49
Xu, H. Y., Wu, D., Li, C., Zheng, L., Liao, X.-Y., Huang, J. S., & Wu, Z. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.12.003 · Cited by 50
Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1
Xie, X., Tang, S.-C., Cai, Y., Pi, W., Deng, L., Wu, G., Chavanieu, A., & Teng, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11185 · Cited by 52
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 51
Friedman, A. A., Amzallag, A., Pruteanu-Malinici, I., Baniya, S., Cooper, Z. A., Piris, A., Hargreaves, L., Igras, V., Frederick, D. T., Lawrence, D. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140310 · Cited by 56
Self-citationPark, S., Hwang, C. Y., Cho, S., Lee, D., Gong, J., Lee, S., Nam, S., & Cho, K. (2019) · FEBS Journal · doi:10.1111/febs.14773 · Cited by 48
Schoumacher, M., Hurov, K. E., Lehár, J., Yan-Neale, Y., Mishina, Y., Sonkin, D., Korn, J. M., Flemming, D., Jones, M. D., Antonakos, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0138-t · Cited by 44
Targeting mutated GTPase KRAS in tumor therapies
Fan, G., Lou, L., Song, Z., Zhang, X., & Xiong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113816 · Cited by 48
Larive, R. M., Moriggi, G., Menacho-Márquez, M., Cañamero, M., de Álava, E., Alarcón, B., Dosil, M., & Bustelo, X. R. (2014) · Nature Communications · doi:10.1038/ncomms4881 · Cited by 48
Oliveira, T. D., Goldhardt, T., Edelmann, M., Rogge, T., Rauch, K., Kyuchukov, N. D., Menck, K., Bleckmann, A., Kalucka, J. M., Khan, S., et al. (2021) · Cancers · doi:10.3390/cancers13051011 · Cited by 43
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“[92] showed that PI3K signaling was most often downstream of IGF-1R in KRAS-mutated colorectal cancer cells and that IGF-1R inhibition did indirectly block PI3K signaling and cooperate with MEK inhibitors to induce cell death.”
BackgroundInfluentialYang, Z., Liao, J., Carter‐Cooper, B., Lapidus, R. G., Cullen, K. J., & Dan, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5664-7 · Cited by 43
Boos, S. L., Loevenich, L. P., Vosberg, S., Engleitner, T., Öllinger, R., Kumbrink, J., Rokavec, M., Michl, M., Greif, P. A., Jung, A., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.10.008 · Cited by 40
Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., Koopmansch, B., MacKay, G. M., Chiavarina, B., Costanza, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.012 · Cited by 38
Kotani, H., Ebi, H., Kitai, H., Nanjo, S., Kita, K., Huynh, T. G., Ooi, A., Faber, A. C., Mino-Kenudson, M. A., & Yano, S. (2015) · Oncogene · doi:10.1038/onc.2015.426 · Cited by 42
Self-citation
Metadata
- Authors
- Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., Wong, K.-K., Cantley, L. C., & Engelman, J. A.
- Affiliations
- Massachusetts General Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Engelman, Jeffrey A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-11-01
- Volume
- 121
- Issue
- 11
- Pages
- 4311-4321
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3204842
- OpenAlex
- W2030733555
- Cited by
- 210
- References
- 56
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 18 · 2020: 19 · 2019: 16 · 2018: 11 · 2017: 21 · 2016: 16 · 2015: 12 · 2014: 26 · 2013: 23 · 2012: 19
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- V Foundation for Cancer Research
- Uniting Against Lung Cancer
- Brigham and Women's Hospital
- Massachusetts General Hospital
- Kanae Foundation for the Promotion of Medical Science
- National Institutes of Health
- National Cancer Institute (P50CA127003, U01CA141457, RC2CA147940, R01CA122794, R01CA140594, CA127003, P50CA090578, K08CA120060, K99CA149169, CA120060-01, R01CA137181, R01CA137008)
- National Institute of General Medical Sciences (R01-GM41890, R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- receptor tyrosine kinase, PI3K/Akt signaling, MEK/ERK signaling, KRAS mutation, colorectal cancer, receptor tyrosine kinase inhibitors, IGF-1 receptor, combination therapy, MEK inhibitors, apoptosis, drug resistance, Akt phosphorylation
- MeSH terms
- Animals, Base Sequence, Humans, Male, Mice, Nude, Mutation, Neoplasm Transplantation, Proto-Oncogene Proteins, Transplantation, Heterologous, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Apoptosis, DNA Primers, ras Proteins, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, MAP Kinase Signaling System, RNA, Small Interfering, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt, Mice, Gene Knockdown Techniques, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.